The battle for British pharmaceutical firm Vectura will not go to auction, after one of the two hopefuls said at the last minute that it would not increase its bid.
US private equity firm Carlyle had made the first move for the Wiltshire-based FTSE 250-listed firm, which makes inhaled medicines and devices to treat respiratory illnesses such as asthma.
But late on Tuesday, it said it would not go beyond its most recent offer of £958m, or 155p per share, saying it considered this “full and fair”.
Simon Dingemans, a managing director in Carlyle’s European buyout advisory group, said: “Carlyle believes its offer is in the best interests of the business and its stakeholders, including its employees, partners and customers, as well as, most importantly, the patients it serves and helps to provide with effective and accessible medicines.”
Carlyle’s bidding rival Philip Morris International (PMI) had offered 165p per share during the weekend, having previously said that such an acquisition would enable it to “expand into products beyond tobacco and nicotine, as part of a natural evolution into a broader healthcare and wellness company”.
AdvertisementPhilip Morris and Carlyle had been set to go through an auction process after the takeover regulator stepped in ready to end the bidding stalemate if there was no resolution by Tuesday at 5pm.
News of Philip Morris’s interest in Vectura has been met with concern from health experts from both sides of the Atlantic and in Europe.
More from Business Bringing in army ‘will not scratch the surface’ of HGV driver shortage COVID-19: New model shortages drive near-record demand for used cars Retail sales grow but remain below pre-pandemic levels Radiator-maker Stelrad warms up plan for £500m flotation Universities not returning to face-to-face teaching should not charge full fees, education secretary Gavin Williamson says Ryan Reynolds on Wrexham football club takeover with Rob McElhenney: ‘I wouldn’t dare call it soccer. I care about my well-being too much’The presidents of the American Lung Association and the American Thoracic Society said it was “reprehensible”, while the British Lung Foundation raised concerns that any takeover by PMI could “significantly hamper” Vectura as a medical research company.
Image: Philip Morris now has the highest bid on the table, although Vectura has not yet announced its next move. Pic: APThe European Respiratory Society added: “It is extremely unethical for a tobacco company to profit from addicting people to its immensely harmful products, then subsequently seek to further profit from the medicines produced to treat harms caused by its own products.”
PMI has said Vectura would operate as an independent unit, adding that it hopes to generate at least $1bn (£730m) in net revenue from “products beyond tobacco and nicotine” by 2025.
Vectura has not yet announced its next move – it could accept PMI’s higher offer, or it could still go with the lower offer from Carlyle.
Shadow health secretary Jonathan Ashworth said earlier on Tuesday: “The Vectura board should exercise their duty of care to all stakeholders and not give in to big tobacco (PMI). If not, ministers should block this take over.”
For its part, Carlyle made it clear it still hoped to be chosen, saying it “encourages shareholders to consider the broader context and the impact of each offer on the company and its wider stakeholders in determining which offer to support”.
Initially Vectura’s board backed the offer Carlyle made in May but, when PMI made its own offer of 150p per share, the board switched its allegiance.
Carlyle made its 155p per share bid for Vectura last week, resulting in the board switching sides again, saying the company might be better positioned under Carlyle’s leadership.
Philip Morris upped its offer to 165p per share during the weekend.
